JPWO2023036745A5 - - Google Patents
Info
- Publication number
- JPWO2023036745A5 JPWO2023036745A5 JP2024514495A JP2024514495A JPWO2023036745A5 JP WO2023036745 A5 JPWO2023036745 A5 JP WO2023036745A5 JP 2024514495 A JP2024514495 A JP 2024514495A JP 2024514495 A JP2024514495 A JP 2024514495A JP WO2023036745 A5 JPWO2023036745 A5 JP WO2023036745A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- antibody
- pharmaceutical composition
- administered
- transplant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241358P | 2021-09-07 | 2021-09-07 | |
| US63/241,358 | 2021-09-07 | ||
| PCT/EP2022/074646 WO2023036745A1 (en) | 2021-09-07 | 2022-09-05 | Method and composition for inducing tolerance |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534926A JP2024534926A (ja) | 2024-09-26 |
| JP2024534926A5 JP2024534926A5 (https=) | 2025-09-09 |
| JPWO2023036745A5 true JPWO2023036745A5 (https=) | 2025-09-09 |
Family
ID=83438688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024514495A Pending JP2024534926A (ja) | 2021-09-07 | 2022-09-05 | 寛容性を誘導するための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20240285756A1 (https=) |
| EP (1) | EP4398929A1 (https=) |
| JP (1) | JP2024534926A (https=) |
| AU (1) | AU2022342702A1 (https=) |
| CA (1) | CA3228514A1 (https=) |
| MX (1) | MX2024002811A (https=) |
| WO (1) | WO2023036745A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024505194A (ja) * | 2021-01-25 | 2024-02-05 | ゼラリオン マルタ リミテッド | 寛容を誘導する方法及び組成物 |
| WO2025207763A1 (en) * | 2024-03-27 | 2025-10-02 | Zelarion Malta Limited | Method and composition for inducing tolerance of transplanted organ or tissue |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002098370A2 (en) | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| AU2014221330B2 (en) * | 2013-02-26 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Combined organ and hematopoietic cells for transplantation tolerance of grafts |
-
2022
- 2022-09-05 AU AU2022342702A patent/AU2022342702A1/en active Pending
- 2022-09-05 MX MX2024002811A patent/MX2024002811A/es unknown
- 2022-09-05 JP JP2024514495A patent/JP2024534926A/ja active Pending
- 2022-09-05 WO PCT/EP2022/074646 patent/WO2023036745A1/en not_active Ceased
- 2022-09-05 EP EP22776895.9A patent/EP4398929A1/en active Pending
- 2022-09-05 CA CA3228514A patent/CA3228514A1/en active Pending
-
2024
- 2024-01-26 US US18/424,381 patent/US20240285756A1/en not_active Abandoned
-
2025
- 2025-05-16 US US19/210,482 patent/US20250276061A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69733960T2 (de) | Verwendung von Antikörpern gegen CD45RO Leukozytenantigen zur Immunmodulation | |
| US10647770B2 (en) | Therapeutic agent for autoimmune diseases comprising PD-1 agonist | |
| MORRIS et al. | A controlled trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months | |
| Debure et al. | One-month prophylactic use of OKT3 in cadaver kidney transplant recipients | |
| Sasaki et al. | Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach | |
| US7939062B2 (en) | Methods for human allografting | |
| JP2025106512A (ja) | 調節性ｔ細胞及びその使用 | |
| JP2002502824A (ja) | 同種移植における補刺激遮断および混合キメラ現象 | |
| Kanda et al. | Alemtuzumab for the prevention and treatment of graft-versus-host disease | |
| JP2014505056A5 (https=) | ||
| FI3556774T3 (fi) | Anti-cd40-vasta-aineita ja niiden käyttötapoja | |
| Kawai et al. | Summary of the third international workshop on clinical tolerance | |
| JP2022137024A (ja) | 移植片対宿主病の処置または予防の方法 | |
| JPH04505919A (ja) | トレランスを誘導するためのモノクローナル抗体 | |
| US20060051357A1 (en) | Tolerance induction with help of a combination of a lfa-1 inhibitor and a costimulation inhibitor and or a mtor inhibitor | |
| Munoz et al. | Rituximab in highly sensitized kidney transplant recipients | |
| US20240109977A1 (en) | Anti-cd38 antibodies and their uses | |
| JP2024534926A (ja) | 寛容性を誘導するための方法及び組成物 | |
| JPWO2023036745A5 (https=) | ||
| JP2002530354A (ja) | 移植の拒絶反応の出現の処置に使用するためのｃｄ２５結合分子 | |
| Hale et al. | Induction of transplantation tolerance in non-human primate preclinical models | |
| JPWO2020178638A5 (https=) | ||
| JP3973360B2 (ja) | 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子 | |
| Diamantstein et al. | Current Stage of Interleukin 2 Receptor Targeted Therapy1 | |
| WO1994023747A1 (de) | Arzneimittel, das antikörper enthält, zur behandlung von t-zell spezifischen immunreaktionen und t-zell-leukämien |